Table 3.
Characteristics of people with PTLD according to anti-PAD2 antibody status.
|
Anti-PAD2+
(n = 39) |
Anti-PAD2–
(n = 242) |
p-Value | |
|---|---|---|---|
| Age (years), mean ±SD | 52.82 ± 15.44 (18.00, 79.00) | 47.34 ± 15.68 (18.00, 82.00) | 0.043 |
| Male n (%) | 20 (51.3%) | 138 (57.0%) | 0.619 |
| White*, n (%) | 34 (87.2%) | 223 (92.9%) | 0.208 |
| Positive two-tier Lyme disease serology*, n (%) | 18 (46.2%) | 101(42.3%) | 0.779 |
| Duration of illness (years), mean ±SD | 3.53 ± 5.23 (0.13, 27.68) | 3.13 ± 3.98 (0.06, 28.59) | 0.579 |
| Duration of antibiotic treatment (years), mean ±SD | 0.36 ± 0.53 (0.04, 2.46) | 0.26 ± 0.41 (0.01, 3.12) | 0.174 |
| Neurologic Lyme, n (%) | 1 (2.6%) | 20 (8.3%) | 0.328 |
Anti-PAD2+, anti-PAD2 antibody positive; Anti-PAD–, anti-PAD2 antibody negative; SD, standard deviation. *Race data was available for n = 240 anti-PAD2- people and positive two-tier Lyme disease serology data was available for n = 239 anti-PAD2- people.